Bdbrut 140mg Capsule

About

Bdbrut 140mg Capsule, likely containing Ibrutinib, is a groundbreaking oral small-molecule inhibitor that specifically targets Bruton's tyrosine kinase (BTK), a critical enzyme involved in the B-cell receptor signaling pathway. This pathway is essential for the survival, proliferation, and migration of malignant B-cells in various hematologic cancers. By forming a covalent bond with a cysteine residue in the BTK active site, ibrutinib irreversibly inhibits BTK activity, thereby disrupting the downstream signaling that drives cancer cell growth. This targeted mechanism leads to the apoptosis of cancerous B-cells and inhibits their adhesion and migration to lymphoid tissues. Ibrutinib has revolutionized the treatment landscape for several B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), and marginal zone lymphoma (MZL), offering a valuable therapeutic option for patients, particularly those with relapsed or refractory disease.

Uses

• Treatment of mantle cell lymphoma (MCL).
• Management of chronic lymphocytic leukemia (CLL).
• Therapy for Waldenström's macroglobulinemia (WM).
• Treatment of marginal zone lymphoma (MZL).

Directions For Use

Take orally once daily with a glass of water. Do not open, break, or chew the capsule.

Benefits

• Targeted therapy for specific B-cell cancers.
• Effective in various types of leukemia and lymphoma.
• Oral administration for patient convenience.
• Can induce durable responses in some patients.
• Offers an alternative for relapsed/refractory cases.
• Improves progression-free survival in certain indications.

Side Effects

• Diarrhea
• Fatigue
• Nausea
• Musculoskeletal pain
• Rash
• Bruising
• Bleeding events (e.g., epistaxis, petechiae)
• Atrial fibrillation
• Hypertension
• Neutropenia (low white blood cell count)
• Thrombocytopenia (low platelet count)
• Increased risk of infections

Safety Measures

• Alcohol - Limit alcohol intake as it may exacerbate gastrointestinal side effects or increase bleeding risk.
• Pregnancy - Contraindicated in pregnancy due to potential fetal harm. Use effective contraception.
• Breastfeeding - Avoid breastfeeding during treatment and for one month after the last dose due to potential harm to the infant.
• Liver - Use with caution and potential dose reduction in patients with hepatic impairment.
• Kidney - Generally safe for use in mild to moderate renal impairment; severe impairment requires careful monitoring.
• Lung - Monitor for new or worsening pulmonary symptoms, including interstitial lung disease.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.